-
1
KLF5 loss sensitizes cells to ATR inhibition and is synthetic lethal with ARID1A deficiency
Published 2025-01-01Get full text
Article -
2
Modelling quiescence exit of neural stem cells reveals a FOXG1-FOXO6 axis
Published 2024-12-01Get full text
Article -
3
-
4
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carbo...
Published 2024-12-01“…ACTOv is open to National Health Service hospitals throughout the UK, recruitment is anticipated to take 36 months across 10 sites and will be managed by the Cancer Research UK and University College London Cancer Trials Centre.Ethics and dissemination The trial has been reviewed and received approval from the London—Dulwich Research Ethics Committee (REC). …”
Get full text
Article -
5
-
6
Author Correction: Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
Published 2025-02-01Get full text
Article -
7
Towards a Molecular Understanding of the Fanconi Anemia Core Complex
Published 2012-01-01Get full text
Article -
8
-
9
-
10
-
11
Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
Published 2021-03-01Get full text
Article -
12
-
13
-
14
Mesenchymal Stem Cell Biodistribution, Migration, and Homing In Vivo
Published 2014-01-01Get full text
Article -
15
-
16
The need for evidence-based, outcome-focused medical imaging research for cancer management
Published 2025-02-01Get full text
Article -
17
-
18
ERK1/2 mitogen‐activated protein kinase dimerization is essential for the regulation of cell motility
Published 2025-02-01Get full text
Article -
19
Author Correction: Normal tissue radioprotection by amifostine via Warburg-type effects
Published 2025-02-01Get full text
Article -
20